NTRP Stock Plunges 80% on Failed Alzheimer’s Treatment Study

NTRP stock

Neurotrope, Inc. (NASDAQ:NTRP) is not starting the week off on the right foot. After announcing that its Alzheimer’s drug failed in its latest trial, NTRP stock tumbled around 80% Monday.

Here’s what we know.

NTRP Stock Plunges 80%

On Monday, September 9, drug developer Neurotrope said its mid-stage Alzheimer’s study did not meet its main goals. According to the US company, its treatment for Alzheimer’s, called Bryostatin-1, did not show a difference in the sample size after 13 weeks compared to those patients who were on a placebo.

Bad news as is, ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.